Cookies on this site

Researchers from Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

Vials of the Covid-19 vaccine © Shutterstock

The life-threatening condition known as thrombosis with thrombocytopenia syndrome (TTS) has been seen in a very small number of people after receiving the adenovirus-based Johnson & Johnson or Oxford-AstraZeneca vaccines, but the risk between different COVID-19 vaccines compared to one another remained unclear.

In a new study published in the BMJ, DPhil student Xintong Li and an international team of researchers used routinely collected health data from five European countries and the USA to produced risk estimates. They found that people who received a first dose of the Oxford-AstraZeneca vaccine ChAdOx1 had a 30% increased risk of thrombocytopenia versus people who received a first dose of the mRNA-based BioNTech, Pfizer vaccine. Although requiring further study, they also saw an increased risk of TTS from the Johnson & Johnson Ad26.COV2 vaccine.

Read the full story on the NDORMS website

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

Five European Research Council (ERC) Synergy Grants awarded to Oxford researchers for ambitious new collaborations

Five Oxford University academics are to co-lead ambitious new research projects backed by European Research Council (ERC) Synergy Grants, part of the EU’s Horizon Europe research and innovation programme. Synergy Grants support groups of two to four outstanding researchers who combine complementary expertise and resources to tackle ambitious scientific challenges that could not be addressed by individual teams alone.

Professor Ole Jensen (Department of Experimental Psychology) and colleagues received €13.6 million to discover when the brain is ready for language and social understanding

The team will use new wearable brain sensors to track cognitive development from before birth to eight years of age.

New 'molecular glue' helps break down antibiotic resistance enzymes in E. coli

Oxford University scientists have discovered a new approach to tackle antimicrobial resistance (AMR), using 'molecular glues' to encourage bacteria to destroy their own resistance-causing enzymes. The study has been published in Angewandte Chemie International Edition.

Stronger immune system may help protect against prostate cancer

Higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer, in a new study led by researchers at the Nuffield Department of Population Health.

The Nuffield Department of Women's & Reproductive Health has published its Biennial Report 2024–26

The Biennial Report 2024–26 highlights two years of research excellence, innovation, collaboration and growth.